NCT06072963 · Phase 2 · RECRUITING
COMMETS- Combination MCI Metabolic Syndrome
This trial is testing whether combining intranasal insulin with semaglutide (the active ingredient in Ozempic and Wegovy) can help slow cognitive decline in older adults who have both mild cognitive impairment and metabolic syndrome. It is a Phase 2 trial, meaning researchers are exploring whether this combination works and is safe, not proving it definitively. The study is based in Israel and requires participants to speak Hebrew.
You may qualify if
- Diagnosis of MCI (based on a MOCA \<27 and a clinical dementia rating scale [CDR] score of 0.5 representing questionable dementia).
- Diagnosis of MetS -requiring a) abdominal obesity (waist circumference >102cm for men and >88cm for women), and b) glucose intolerance (fasting glucose>110 mg/dL) and at least one of the following-c) dyslipidemia (high triglycerides [>150 mg/dL] and low HDL [\<40mg/dL for men and \<50 mg/dL for women]), or d) elevated blood pressure (>130/>85 mmHg).
- Fluent in Hebrew
- The study requires an active study partner
You're excluded if
- Diabetes (of any type)
- Taking medications that may affect glucose metabolism (including a GLP-1RA).
- Diagnosis of dementia and its subtypes, conditions that may directly affect cognition,
- short life expectancy or a medical condition that precludes consistent participation in the study,
- contraindications to either insulin or Semaglutide.
- Medications that may affect glucose metabolism such as corticosteroids.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2024-03-22